Nucleic Acid Based Therapeutics Market Size, Growth, Report 2022-2030

According to Latest Study, the global nucleic acids based therapeutics market was valued at USD 536 million in 2021 and it is predicted to surpass around USD 771.52 million by 2030 with a CAGR of 4.13% from 2022 to 2030.

Nucleic acid based therapeutics (NAT) target the genetic basis of the disease for treatment. Technological advancement and human genome understanding have allowed the development of many nucleic acids based therapeutics and even the approvals by US FDA and EMA demonstrates the potential to treat diseases genetically. NAT even allows long-lasting effects as it involves the cellular mechanism of gene silencing, addition, replacement, or editing.

Immediate Delivery Available | Get the sample copy of report@

The rising investments in the healthcare sector have also driven the research toward the treatment of many diseases and disorders. The increasing rate of chronic diseases among the population along with the genetic disorders has resulted in an upswing in research activities for building better healthcare settings worldwide. NAT offers a targeted and effective solution for any diseased condition. The COVID-19 pandemic also fueled the NAT market, as the successful utilization of mRNA vaccines as one of the preventive treatments boosted the healthcare industry to recognize the importance and efficacy of nucleic acid based therapies.

Nucleic acid based therapeutics market is segmented based on the following technologies;

  • RNA targeted therapeutics,
  • Gene therapies,
  • Epigenetic and microRNA modulating therapies,
  • Genome editing therapies,
  • Others

Scope of The Report

Report Coverage


Market Size in 2021

USD 536 million

Revenue Forecast by 2030

USD 771.52 million

Growth rate from 2022 to 2030

CAGR of 4.13%

Base Year


Forecast Period

2022 to 2030


Technology, Application, End-user, Region

Companies Covered

Silence Therapeutics plc, Ionis Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, BioNtech, Moderna Inc., and Alnylam Pharmaceuticals, Inc. among others


Many approved and late stage clinical programs are using RNA targeted treatment platform. Use of ASO (antisense oligonucleotides) or siRNA (short interfering RNA) for treatment of muscular atrophy has been approved by FDA and EMA. The widespread knowledge of the human genome and thus the advent of gene therapies for development & clinical use approval has boosted in the past years. The well-used examples of Kymriah, Yescarta, Tecartus for treatment of types of leukemia or lymphoma demonstrates the growing use of gene therapies. Novel identification of therapeutic targets in the non-coding genome are arising from the epigenetics research. The importance of genome editing techniques via CRISPR/Cas has been established in many applications such as stem cell. These gene editing therapeutics are the next generation of NAT market. Furthermore, other technologies such as LNPs (lipid nanoparticles), adeno-associated virus (AAV) vectors and many more also hold some significance in the NAT market.

The advancement in molecular technologies and the continuous omics-based research has resulted in huge investments by many companies. The nucleic acid based therapeutics market is highly competitive and the market participation is via many strategic business models. Acquisitions, partnerships or collaborations are the leading revenue generators in the market. For instance, in August 2022, Merck & Co. announced that it has collaborated with Orna Therapeutics to develop a new class of therapeutic RNA. The collaboration involved the discovery, development and commercialization of new RNA-based therapeutics for vaccines, infectious disease as well as oncology programs. 

Market dynamics 


The treatment for chronic illnesses is developing immensely. However, the growth of treatments for genetic disease is slow. There are only a few and poor treatments to treat genetic diseases. The poor treatments available for genetic disorders are a crucial driver for the nucleic acid-based therapeutics market. The nuclei based therapeutics treats the inactive genes in the body. It works with the body molecules to treat such disorders. It combines with gene sequence for treatment. The nucleic acid-based is one of the effective treatments available for gene disorders. The understanding of human genetics is rising in recent years.

Technological advancements are more that enables efficient study of human genetics. It is leading to more adoption of new treatments for genetic disorders. The enhanced understanding of nucleic acid-based therapeutics is a crucial driver for the nucleic acid-based therapeutics market. The capabilities to handle molecule tissues are surging. The capabilities of mapping human tissue are a crucial driver for the market. All these factors will lead to the high growth of the nucleic acid-based therapeutics market. The demand rate will be tremendous for the market due to all these market drivers. Also, the nucleic acid-based therapeutics market revenue will be exceptional due to these market drivers. 

Immediate Delivery Available | Buy this Premium Research Report@


The software in the therapeutic market is increasing the growth opportunities. The adoption of software brings plenty of favourable changes to the health sector. This software mimics the molecular structure of the human body. With precise mimicking the ways to treat and research is effortless. Within rising investment for medical technologies the scope for nucleic acid-based therapeutics is high. More extensive research or the market is possible through the technology. As per the Nucleic acid-based therapeutics market analysis development of a virtual drug is immense in the forecast period. The market will have a wide range of end-users with improvements in virtual drugs. The technologies in the market help to sequence and synthesize RNA. With technological enhancements, more variety in the nuclei acid-based market is expected. The nucleic acid binds with the RNA strands of the body. Gene silencing and testing are effective with technological developments in the market. These market growth opportunities will lead to a remarkable expansion rate. 


The nucleic acid-based market requires extensive research. The high cost of research is a crucial restraint for the market. Nucleic based therapeutics market is highly sophisticated. High failure rates are common in this sector. The high cost of research and cost of loss impacts the market profitability. The high cost of research affects the demand and growth of the market. 

The constant changes at generic levels and contamination makes it difficult to discover efficient treatments. There is a poor source to understand human genetics. The technologies relating to genetics are expensive. The complexities involved in the market leads to losses in the market. These restraints can affect the nucleic acid-based therapeutics market growth rate in the forecast period. 


The nucleic acid-based is one of the expensive treatments in the world. Genetic disorders are one of the toughest diseases to treat. Due to the complexities, the treatments are expensive. Due to high expenses, the demand and supply of the market are affected.

Further, there are regulatory norms that affect the overall growth of the nucleic acid-based therapeutics market. Due to the regulatory norms, the launch of nucleic acid-based therapies is delayed. Also, there are commodities in drug delivery of the market. The launch of inefficient drugs is reducing the adoption of nucleic acid-based treatment. These are the significant challenges in the market during the forecast period. It can affect the overall profitability rate of the nucleic acid-based therapeutics market in the upcoming years. 

Key Players

  • Silence Therapeutics plc
  • Ionis Pharmaceuticals
  • Novartis 
  • Arrowhead Pharmaceuticals
  • BioNtech
  • Moderna Inc.
  • Alnylam Pharmaceuticals, Inc.
  • others

Market Segmentation

  • By Technology
    • RNA targeted therapeutics
    • Gene therapies
    • Epigenetic and microRNA modulating therapies
    • Genome editing therapies
    • Others
  • By Application
    • Autoimmune Disorders
    • Infectious Diseases
    • Genetic Disorders
    • Cancer
    • Others
  • By End-user
    • Hospitals & Clinics
    • Academic & Research Institutes
    • Others
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and Africa (MEA)

Click Here to View Full Report Table of Contents

Immediate Delivery Available | Buy this Premium Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333



Back to news